In a landmark achievement for regenerative medicine and developmental biology, an international team of researchers has unveiled the first comprehensive…
Read More

In a landmark achievement for regenerative medicine and developmental biology, an international team of researchers has unveiled the first comprehensive…
Read More
Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…
Read More
Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…
Read More
In a landmark achievement for regenerative medicine and developmental biology, researchers from the Wellcome Sanger Institute and their international collaborators…
Read More
Eli Lilly and Company utilized the prestigious platform of the American Diabetes Association’s (ADA) annual meeting to unveil groundbreaking Phase…
Read More
In a landmark achievement for regenerative medicine and developmental biology, an international consortium of researchers has published the first comprehensive…
Read More
The Dawn of a New Era in Metabolic Disease Management The announcement at the ADA meeting highlighted retatrutide’s remarkable efficacy,…
Read More
Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…
Read More
Researchers from the Wellcome Sanger Institute, in collaboration with an international network of scientists, have unveiled the first comprehensive "blueprint"…
Read More
Stockholm, Sweden – Researchers at the esteemed Karolinska Institutet in Stockholm, Sweden, have achieved a significant breakthrough in understanding the…
Read More